Artemis Medicare Services (BOM:542919) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:542919 Artemis Medicare Services Ltd BOM:542919
89 GF Score
Price ₹272.40
GF Value ₹265.43
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Artemis Medicare Services Research & Development?

Artemis Medicare Services BOM:542919 -1.41% 89 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:542919 with a GF Score™ of 89/100 and a GF Value™ of ₹265.43 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Artemis Medicare Services's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Artemis Medicare Services  (BOM:542919) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Artemis Medicare Services Research & Development Related Terms

Artemis Medicare Services Research & Development Historical Data

* Premium members only.

The historical data trend for Artemis Medicare Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artemis Medicare Services Research & Development Chart

Artemis Medicare Services Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.07 36.42 28.37 16.56 0.00

Artemis Medicare Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:542919
89GF Score
Artemis Medicare Services Ltd BOM:542919
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artemis Medicare Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Artemis Medicare Services (BOM:542919) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Artemis Medicare Services and its competitors.
Is Artemis Medicare Services' Research & Development too high?
Artemis Medicare Services' current Research & Development is ₹0 Mil. Overall, Artemis Medicare Services has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Artemis Medicare Services' Research & Development compare to HCA and THC?
Artemis Medicare Services' Research & Development of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Artemis Medicare Services and its competitors. Artemis Medicare Services's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artemis Medicare Services stock overvalued right now?
Based on GuruFocus' analysis, Artemis Medicare Services (BOM:542919) is currently considered Fairly Valued. The stock's GF Value™ is ₹265.43, compared to a current price of ₹272.40 — trading 2.6% above its estimated fair value. The current Research & Development is ₹0 Mil. Artemis Medicare Services' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Artemis Medicare Services (BOM:542919), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Artemis Medicare Services (BOM:542919) Overvalued in 2026?

Based on GuruFocus' analysis, Artemis Medicare Services stock appears to be overvalued. The current stock price of ₹272.40 is trading 2.6% above its estimated GF Value™ of ₹265.43. GuruFocus considers Artemis Medicare Services to be Fairly Valued.

Key valuation signals for BOM:542919:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹265.43 vs. price of ₹272.40 (2.6% above fair value)
  • GF Score™: 89/100 with 4 warning signs

No single metric tells the full story. See the BOM:542919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Artemis Medicare Services Business Description

Address Artemis Hospital, Sector 51, Gurugram, HR, IND, 122001
Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals. The hospital provides treatments for Allergy and Immunology, Blood (Haematology), Bones, Muscles and Joints (Orthopaedics), Brain, Spine and Nervous System, Cancer (Oncology), Circulatory (Vascular), Digestive (Gastroenterology), Endocrine, Diabetes And Metabolism, Dermatology, Heart (Cardiology), Infectious Diseases, Kidneys (Renal), Lung (Pulmonary), Mouth, Teeth And Face (Oral And Maxillofacial), Obstetrics And Gynecology, Psychiatry, Rheumatology (Arthritis And Joint Disease), Surgery, and Urology. The company derives revenue mainly from Healthcare Services through the operation of multi-specialty Hospitals.
89GF Score

Get the complete analysis for BOM:542919

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹272.40
Price
₹265.43
GF Value